<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01795742</url>
  </required_header>
  <id_info>
    <org_study_id>MU-HR-2433</org_study_id>
    <nct_id>NCT01795742</nct_id>
  </id_info>
  <brief_title>Equivalence of a Human-Powered Nebulizer to an Electric Nebulizer</brief_title>
  <official_title>Equivalence of a Human-Powered Nebulizer to an Electric Nebulizer in the Treatment of Mild to Moderate Asthma in El Salvador</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marquette University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marquette University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an equivalence study comparing an electric nebulizer with a human-powered
      nebulizer--one that does not need electricity--in the treatment of mild to moderate asthma
      exacerbations in a regional clinic in San Salvador, El Salvador.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design is to treat individuals suffering from mild to moderate exacerbations of
      asthma with nebulized salbutamol (2.5mg). Subjects will receive nebulization using either an
      electric nebulizer compressor or a human-powered nebulizer compressor. Improvement in peak
      expiratory flow will be the primary endpoint. Blood oxygenation levels as measured by pulse
      oximetry will be a secondary endpoint of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Peak Expiratory Flow</measure>
    <time_frame>From before to after nebulizer treatment lasting approximately 30 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in blood oxygenation as measured by pulse oximetry</measure>
    <time_frame>From before to after nebulizer treatment lasting about 30 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Electric Nebulizer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulmo-Aide Model 5650D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Human-Powered Nebulizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human-Powered</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Human-Powered Nebulizer</intervention_name>
    <arm_group_label>Electric Nebulizer</arm_group_label>
    <arm_group_label>Human-Powered Nebulizer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suffering from Mild or Moderate Asthma symptoms

          -  Increased respiratory rate, but not over 30 breaths per minute

          -  Reduced peak expiratory flow rate, but not less than 60% of normal

          -  Oxygen saturation levels reduced but greater than 90%

        Exclusion Criteria:

          -  Any other respiratory condition that would interfere with nebulizer treatment

          -  If any other medication is being taken at the time

          -  Pregnant women or women who may think they might be pregnant

          -  Never taken salbutamol before
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars E Olson, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marquette University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Nacional San Bartolo</name>
      <address>
        <city>Ilopango</city>
        <state>San Salvador</state>
        <country>El Salvador</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>El Salvador</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2013</study_first_submitted>
  <study_first_submitted_qc>February 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2013</study_first_posted>
  <last_update_submitted>February 18, 2013</last_update_submitted>
  <last_update_submitted_qc>February 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Marquette University</investigator_affiliation>
    <investigator_full_name>Lars Olson</investigator_full_name>
    <investigator_title>Associate Professor of Biomedical Engineering</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Nebulizers</keyword>
  <keyword>Salbutamol</keyword>
  <keyword>Developing Countries</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

